CliffBio
small molecule

RAPLON

RAPACURONIUM BROMIDE

Loss of exclusivity—loss of exclusivity
CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand nameRAPLON
Active ingredientRAPACURONIUM BROMIDE
Strength200MG/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalAugust 1999
Marketing statusDISCN

More from Organon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RAPLON patent cliff — loss of exclusivity — | CliffBio